Latest news with #iBio
Yahoo
24-06-2025
- Health
- Yahoo
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake in a mouse model of obesity by 60% (p<0.05), equivalent to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide (67%). The effect on food intake was monitored over various time points in this side-by-side study with the amylin agonist iBio discovered and a DACRA peptide. The study marks the third target to emerge from iBio's partnership with AstralBio. The successful iBio-AstralBio collaboration now includes multiple novel engineered antibody agonists with a wide range of profiles targeting the amylin receptor, a heterodimeric G protein-coupled receptor (GPCR). 'Emerging clinical data suggest selective activation of the amylin receptor—rather than dual agonism of the amylin and calcitonin receptors—can match or even exceed DACRA efficacy, with improved tolerability,' said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. 'Our AI-enabled antibody discovery platform allows us to precisely dial in that selectivity and specifically target the amylin receptor and even its subtypes. This new program underscores iBio's commitment to developing next-generation therapies to address the limitations of current treatments in the fast-growing obesity market.' Amylin, or islet amyloid polypeptide (IAPP), is a pancreatic B-cell hormone shown to regulate satiety and delay gastric emptying. When activated through receptor agonism, it enhances meal-ending metabolic signals that prolong the feeling of fullness. Amylin receptors (AMYRs), composed of heterodimeric GPCRs, represent a compelling therapeutic target for obesity and other cardiometabolic diseases. iBio's approach leverages its proprietary Drug Discovery Platform and advanced AI platform to discover innovative antibodies with exceptional selectivity and potency. This allowed the discovery of molecules capable of agonizing a single AMYR subtype or having balanced agonism at multiple receptors (i.e., DACRA-like agonism profile). This precise and versatile GPCR agonist discovery is thought to allow the identification of a best-in-class therapeutic candidate for an optimal profile of quality weight loss, gastrointestinal tolerability, and lean mass preservation. Other amylin analogs currently under clinical development have achieved reduced body weight in obese patients of up to 22.7%1 when used in combination with semaglutide and 11.8%2 as monotherapy. By targeting a different set of signaling pathways, this novel approach holds promise not only for enhancing the weight-loss efficacy seen with GLP-1 receptor agonists but also as a monotherapy option for patients who are intolerant or insufficiently responsive to GLP-1-based interventions. References 1. 2. Conference Call Details iBio will host a conference call today, June 24, at 8:30 a.m. ET to discuss new pre-clinical data and the Company's obesity pipeline. The webcast of the live call may be accessed on the Investors section of the iBio website at A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation. To join the live call, participants need to access this link for dial-in numbers and a unique participation code. About iBio, Inc. iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit or follow us on LinkedIn. Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases, accelerating the development of novel antibodies for obesity and cardiometabolic diseases in partnership with AstralBio Inc., the positive early results supporting iBio's approach to antibody-based amylin receptor agonism for the treatment of obesity, iBio's engineered antibody potentially offering differentiated advantages in dosing and tolerability, developing next-generation therapies to address the limitations of current treatments in the fast-growing obesity market, leveraging iBio's proprietary Drug Discovery Platform and advanced AI platform to discover innovative antibodies with exceptional selectivity and potency and iBio's approach targeting the amylin receptor holding promise not only for enhancing the weight-loss efficacy seen with GLP-1 receptor agonists but also as a monotherapy option for patients who are intolerant or insufficiently responsive to GLP-1-based interventions. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of amylin receptor to be a successful target for obesity and cardiometabolic diseases; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Corporate Contact:iBio, Relationsir@ Media Contacts:Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-06-2025
- Business
- Yahoo
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, IBIO-600, new preclinical data on Activin E and, more safe and effective treatment webcast of the live call may be accessed on the Investors section of the iBio website at A replay of the webcast will be available on the iBio website for approximately 60 days following the join the live call, participants need to access this link for dial-in numbers and a unique participation code. About iBio, Inc. iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit or follow us on LinkedIn. Forward-Looking Statements Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding pioneering the next generation of antibody medicines, which are potentially better tolerated therapies with more sustainable efficacy, and Activin E and amylin agonist, which are promising pathways for more safe and effective treatment options. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Corporate Contact: iBio, Inc. Investor Relations ir@ Media Contacts: Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC (858) 717-2310 or (646) 942-5604
Yahoo
11-05-2025
- Business
- Yahoo
Insider Buyers At iBio Likely Disappointed With 23% Slide
Insiders who bought US$655.0k worth of iBio, Inc.'s (NASDAQ:IBIO) stock at an average buy price of US$2.72 over the last year may be disappointed by the recent 23% decrease in the stock. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$186.2k, which is not what they expected. While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The Independent Director Antonio Parada made the biggest insider purchase in the last 12 months. That single transaction was for US$500k worth of shares at a price of US$2.72 each. That means that an insider was happy to buy shares at above the current price of US$0.77. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels. While iBio insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for iBio There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, iBio insiders have about 2.6% of the stock, worth approximately US$332k. I generally like to see higher levels of ownership. The fact that there have been no iBio insider transactions recently certainly doesn't bother us. However, our analysis of transactions over the last year is heartening. While we have no worries about the insider transactions, we'd be more comfortable if they owned more iBio stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. When we did our research, we found 7 warning signs for iBio (5 are significant!) that we believe deserve your full attention. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-05-2025
- Health
- Yahoo
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs. GLP-1 receptor agonists are effective at promoting weight loss. However, they can also reduce lean body mass, including muscle, which may limit some of the intended health benefits. In contrast, fat-specific weight loss is considered a higher-quality form of weight loss. It reduces fat—linked to lower risk of heart and metabolic diseases—while preserving muscle, which helps maintain strength, supports a healthy metabolism, and may prevent or reduce weight regain over time. 'We believe achieving high-quality weight loss, by reducing fat mass while preserving muscle, is essential in addressing the obesity epidemic,' said Martin Brenner, DVM, PhD, Chief Executive Officer and Chief Scientific Officer of iBio. 'For example, a person with a BMI of 30 is classified as obese and often has a body fat percentage exceeding 25%. Reducing fat by 25% while maintaining muscle mass and strength could shift them into a healthier weight category without compromising physical function.' The study also analyzed specific fat depots in obese mice and found a significant 31% reduction in subcutaneous fat. More notably, reductions of 34% and 37% were observed in the epididymal and retroperitoneal fat depots, respectively—both of which are forms of visceral fat closely linked to increased risk of cardiometabolic disease. When combined with a GLP-1 receptor agonist, the Activin E antibody produced additive effects, reducing total fat mass by 77%. Subcutaneous fat loss increased to 74%, while visceral fat depots—epididymal and retroperitoneal—were reduced by 69% and 81%, respectively. The data was presented at the 14th International BMP Conference that occurred May 2–6 in Philadelphia, Pennsylvania. About iBio, Inc. iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit or follow us on LinkedIn. Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the therapeutic potential of Activin E as a target for cardiometabolic disorders and obesity; Activin E being a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; plans to rapidly advance testing of the antibody in more complex models; the in-licensed antibody being the first functional inhibitor of Activin E; inhibiting Activin E-mediated signaling offering a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation; Activin E, along with amylin, GLP-1 and others, having the potential to be targeted simultaneously to yield synergistic benefits for patients; and the antibody having the potential to deliver meaningful benefits to patients. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Activin E to be a successful target for cardiometabolic disorders and obesity and iBio's antibody to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. Corporate Contact:iBio, Relationsir@ Media Contacts:Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, 717-2310 or (646) 942-5604Sign in to access your portfolio
Yahoo
01-04-2025
- Business
- Yahoo
iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025
We recently published a list of . In this article, we are going to take a look at where iBio, Inc. Common Stock (NASDAQ:IBIO) stands against other stocks insiders were buying in Q1 2025. About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while the blue-chip companies gained 0.9%. Meanwhile, the Nasdaq Composite dropped 0.5%. Some stocks were recovering from Friday losses after inflation data came in higher than expected, coupled with weak consumer sentiment, which heightened concerns about the U.S. economy's stability, according to Investopedia. As investors react to daily market changes, ongoing uncertainty continues to affect the market. During such times, insider trading often garners attention, as executive purchases of company stock can signal optimism about the company's prospects. However, insider sales do not always indicate a lack of confidence—they may be influenced by personal financial reasons or a need for diversification. Executives often follow pre-arranged plans, like 10b5-1, to ensure transparency. While insider trading can offer valuable insights, it should be considered alongside a company's financial health, market conditions, and industry shifts. What are some of the stocks insiders have been buying the most in the first quarter of the year? To find out, we used Insider Monkey's insider trading stock screener, focusing only on stocks where at least five insiders had purchased shares in January, February, and March. From there, we ranked the 20 stocks with the highest number of insiders purchasing shares. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the average price per share of these purchases and the stock's market capitalization. A biotechnologist in a lab wearing an apron and safety glasses, working on a biopharmaceutical process. Market Cap: $40.68 million Number of insiders buying: 7 iBio is a biotechnology firm that leverages AI and advanced computational biology to develop biopharmaceuticals targeting cardiometabolic diseases, obesity, cancer, and other challenging conditions. The San Diego, California-based company uses proprietary 3D modeling and innovative drug discovery platforms to build a pipeline of novel antibody treatments for unmet medical needs. It is also one of the 12 best biotech penny stocks to invest in. For the second quarter of fiscal 2025, iBio reported $200,000 in revenue and a net loss of $4.36 million, compared to a net loss of $4.49 million in the same period last year. Earlier this year, iBio announced a collaboration with AstralBio Inc. to develop an antibody that targets Activin E, a potential treatment for cardiometabolic disorders and obesity, using iBio's proprietary Machine-Learning Antibody Engine. In January, seven insiders, including the company's CFO, acquired approximately $654,995 worth of iBio shares at an average price of $2.72 per share. Year-to-date, the stock gained 59.59%, trading at $3.91 per share. Over the past 12 months, iBio shares rose 16.72%. Based on the estimates of three analysts, iBio stock is a 'Strong Buy' with a price target of $4.87. The average price target suggests a 27.49% upside from the latest price. Overall, IBIO ranks 18th on our list of stocks insiders were buying in Q1 2025. While we acknowledge the potential of IBIO our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBIO but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
